Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
PURPOSE: The use of 90Y-microspheres to treat unresectable liver metastases originating from a variety of neuroendocrine tumors was reviewed. MATERIALS AND METHODS: This is a retrospective review from 10 institutions of patients given 90Y-microsphere therapy for neuroendocrine hepatic metastases. Physical, radiographic, biochemical, and clinical factors associated with treatment and response were examined. All patients were followed with laboratory and imaging studies at regular intervals until death, or censured whether other therapy was given after brachytherapy. Toxicities (acute and late) were recorded, and survival of the group determined. RESULTS: A total of 148 patients were treated with 185 separate procedures. The median age was 58 years (26-95 years) at treatment with median performance status of Eastern Cooperative Oncology Group (0). The median activity delivered was 1.14 GBq (0.33-3.30 GBq) with a median of 99% of the planned activity able to be given (38.1%-147.4%). There were no acute or delayed toxicity of Common Terminology Criteria for Adverse Events v3.0 grade 3 in 67% of patients, with fatigue (6.5%) the most common side effect. Imaging response was stable in 22.7%, partial response in 60.5%, complete in 2.7% and progressive disease in 4.9%. No radiation liver failure occurred. The median survival is 70 months. CONCLUSION: Radioembolization with 90Y-microspheres to the whole liver, or lobe with single or multiple fractions are safe and produce high response rates, even with extensive tumor replacement of normal liver and/or heavy pretreatment. The acute and delayed toxicity was very low without a treatment related grade 4 acute event or radiation induced liver disease in this modest-sized cohort. The significant objective response suggests that further investigation of this approach is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of 8305 cases of carcinoid tumors
Modlin, I. M., & Sandor, A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2 · Cited by 1,200
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Salem, R., & Thurston, K. G. (2006) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000233785.75257.9a · Cited by 724
Self-citationKennedy, A., Nag, S., Salem, R., Murthy, R., McEwan, A. J., Nutting, C., Benson, A., Espat, J., Bilbao, J. I., Sharma, R. A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.060 · Cited by 676
Self-citationThe diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674 · cited 1×
“Conventional therapies have largely been considered palliative supportive care.(8) However, aggressive local treatments in the liver have demonstrated improvements in both symptomatic control and survival.”
BackgroundHepatic neuroendocrine metastases: does intervention alter outcomes?1
Chamberlain, R. S., Canes, D., Brown, K. T., Saltz, L., Jarnagin, W., Fong, Y., & Blumgart, L. H. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00222-2 · Cited by 622
Gray, B., Van Hazel, G., Hope, M., Burton, M., Moroz, P., Anderson, J., & Gebski, V. (2001) · Annals of Oncology · doi:10.1023/a:1013569329846 · Cited by 526
Hepatic resection for metastatic neuroendocrine carcinomas
Que, F. G., Nagorney, D. M., Batts, K. P., Linz, L. J., & Kvols, L. K. (1995) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80107-x · Cited by 462
Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Self-citationKennedy, A. S., Nutting, C., Coldwell, D., Gaiser, J., & Drachenberg, C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.004 · Cited by 407
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Self-citationÖberg, K., Knigge, U., Kwekkeboom, D., & Perren, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 524
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Self-citationNeuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2056 · Cited by 304
(2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0050 · Cited by 292
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
Ahmed, A., Turner, G., King, B., Jones, L., Culliford, D., McCance, D., Ardill, J., Johnston, B. T., Poston, G., Rees, M., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0042 · Cited by 274
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/154541 · Cited by 69
“is the stabilization of extensive disease allowing for longer survival periods [38].”
Background
Metadata
- Authors
- Kennedy, A. S., Dezarn, W. A., McNeillie, P., Coldwell, D., Nutting, C., Carter, D., Murthy, R., Rose, S., Warner, R. R. P., Liu, D., Palmedo, H., Overton, C., Jones, B., & Salem, R.
- Venue
- American Journal of Clinical Oncology
- Published
- 2008-06
- Volume
- 31
- Issue
- 3
- Pages
- 271-279
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W2069999129
- Cited by
- 424
- References
- 40
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.